CBS 2019
CBSMD教育中心
中 文

Scientific Library

Abstract

Recommended Article

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT) Management of No-Reflow Phenomenon in the Catheterization Laboratory Pericardial effusion is correlated with clinical outcome after pulmonary artery denervation for pulmonary arterial hypertension Advances in Coronary No-Reflow Phenomenon-a Contemporary Review Clarification of Myocardial Infarction Types Incidence of contrast-induced acute kidney injury in a large cohort of all-comers undergoing percutaneous coronary intervention: Comparison of five contrast media Location of the culprit coronary lesion and its association with delay in door-to-balloon time (from a multicenter registry of primary percutaneous coronary intervention) Chronic total occlusion intervention of the non-infarct-related artery in acute myocardial infarction patients: the Korean multicenter chronic total occlusion registry

Guideline2016 Jan 1;37(1):67-119.

JOURNAL:Eur Heart J. Article Link

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)

Galiè N, Humbert M, ESC Scientific Document Group. Keywords: Chronic thromboembolic pulmonary hypertension; Congenital heart disease; Connective tissue disease; Endothelin receptor antagonists; Guidelines; Heart failure; Left heart disease; Lung disease; Phosphodiesterase type 5 inhibitors; Prostacyclin analogues; Pulmonary arterial hypertension; Pulmonary hypertension; Respiratory failure

Full Text PDF